Condition

Breast Cancer Stage II

ClinicalTrials.gov condition label

Clinical trials55

Recruiting17

Common interventions25

Lead sponsors shown15

Clinical trials

55 shown

A Study of the TheraBionic P1 Device in Breast CancerNCT07218432 · 2026-10-01

Capecitabine in ER+/HER2-negative Breast CancerNCT07631052 · 2026-07-29

Effect of Meal Timing During Cancer Treatment in Patients in Alaska: A Randomized Clinical TrialNCT06802172 · 2026-07-23

Neoadjuvant, SBRT With Intratumoural Pembrolizumab Followed by Neoadjuvant Chemotherapy in Breast CancerNCT07188246 · 2026-01-19

Memantine and Exercise to Improve Cognitive Function and Modulate Biological Pathways of Cognitive Decline During Chemotherapy in Breast CancerNCT06727773 · 2025-08-19

A Phase Ib/II Study to Evaluate Multiple Combination Therapies of FWD1802 in Patients With ER+/HER2- BCNCT07002177 · 2025-06-01

A New Tool to Promote Patient's Engagement in Their Healthcare ProcessNCT06762496 · 2025-01-22

A Study of Language Interpretation Solutions for People With Breast CancerNCT06721065 · 2024-12-02

Predicting Response to Neoadjuvant Endocrine Therapy (Neo-PREDICT)NCT06806930 · 2024-10-01

Tart Cherry Juice as a Dietary Supplement for the Prevention of Paclitaxel-Induced NeuropathyNCT06268665 · 2024-08-15

Optimizing Surgical Decisions in Young Adults With Breast CancerNCT06275126 · 2024-03-13

Virtual Rehabilitation for Cancer SurvivorsNCT05898789 · 2023-07-07

Evaluation of Radiobiological Effects in Skin Toxicities for Breast Cancer Patients With Pencil Beam Scanning Proton TherapyNCT06006806 · 2023-07-07

Evaluating and Monitoring Immune and Clinical Responses in Early-Stage Triple Negative Breast Cancer Undergoing Neoadjuvant Chemo-immunotherapy With PembrolizumabNCT05877859 · 2023-05-30

Correlation of Clinical Response to Pathologic Response in Patients With Early Breast CancerNCT05020860 · 2023-04-18

Adjuvant Chemoradiation and Biomarkers of Response in High-risk Breast CancerNCT05288777 · 2022-07-11

Ways of Retaining the Inframammary Fold in Implant-based Breast SurgeryNCT06931548 · 2022-03-01

Herbs & Supplements in Breast Cancer Usage, Impact, and Personalized Approaches for Diverse PopulationsNCT06926530 · 2026-10-01

NOT_YET_RECRUITING

Pembrolizumab Adjuvant in Patients With Early-stage Triple Negative Breast Cancer With Residual Disease After Neoadjuvant Pembrolizumab Plus ChemotherapyNCT07486687 · 2026-04-01

NOT_YET_RECRUITING

Study Assessing the Efficacy and Safety of cANnabidiol Oral Solution for Joint Pain of Adjuvant enDOcrine theRApy in Patients With Early Breast CancerNCT06787118 · 2025-12-01

NOT_YET_RECRUITING

CARE (Chemotherapy Alopecia REduction)NCT07201389 · 2025-09-24

ACTIVE_NOT_RECRUITING

Role of Triggering Receptor Expressed on Myeloid Cells (TREM-1) as a Novel Biomarker in Human Epidermal Growth Factor Receptor -2 (HER-2) Negative Breast Cancer: a Molecular and Clinical StudyNCT06950671 · 2025-09-15

NOT_YET_RECRUITING

The Efficacy and Safety of CDK4/6 Inhibitors in Combination with Endocrine Therapy in the Neoadjuvant TreatmentNCT06810492 · 2025-04-01

NOT_YET_RECRUITING

Abbreviated MBCT for Depression in Older Black or African American Breast Cancer SurvivorsNCT06336538 · 2025-03-21

ACTIVE_NOT_RECRUITING

EFFECT OF KINESIO TAPING AND LASER THERAPY IN PATIENT WITH LYMPHEDEMA ON GIRTH MEASUREMENTNCT06808178 · 2025-02-01

Improvement of Quality of Life Through Supportive Treatments for Hormone Therapy - Related Symptoms in Patients With Early Breast CancerNCT06407401 · 2024-12-01

NOT_YET_RECRUITING

The Effect of Breathing Exercise on Sleep and Stress Levels in Women With Breast Cancer Receiving Chemotherapy TreatmentNCT06318455 · 2023-11-01

Ultrahypofractionation and Normal Tissue ToxicityNCT05912231 · 2023-08-15

ACTIVE_NOT_RECRUITING

Implantable Microdevice for TNBC - Pilot StudyNCT05774886 · 2023-05-01

Patient Reported Outcomes After Oncoplastic Breast Conserving SurgeryNCT05724758 · 2023-03-01

Positron Emission Tomograph(PET) Imaging Explores the Role of SF-DEVD-2 in Monitoring Tumor EfficacyNCT05828238 · 2023-01-01

Anlotinib Combined With Chemotherapy and Neoadjuvant Therapy for Hormone Receptor-positive HER-2 Negative Breast CancerNCT05558722 · 2022-12-05

ACTIVE_NOT_RECRUITING

Preventing Chemotherapy-Induced Peripheral Neuropathy With Acupuncture (PACT Trial)NCT05528263 · 2022-09-08

The Effectiveness of Psychological Interventions in Psycho-neuroendocrine-immune Network in Breast Cancer SurvivorsNCT05406531 · 2022-06-06

Neoadjuvant and Adjuvant Ribociclib and ET for Clinically High-risk ER+ and HER2- Breast CancerNCT05296746 · 2022-05-03

ACTIVE_NOT_RECRUITING

A Study of Oleogel-S10 Gel for the Treatment of Radiation Dermatitis in People With Breast CancerNCT05190770 · 2021-12-15

Feasibility of a Remotely-Delivered Yoga Intervention on Cognitive Function in Breast Cancer SurvivorsNCT05180656 · 2021-12-13

Study of Cardiopulmonary Exercise Testing in Women Who Have HER2-Positive Breast Cancer With Mild CardiotoxicityNCT05036252 · 2021-08-27

ACTIVE_NOT_RECRUITING

Taking AIM at Breast CancerNCT04720209 · 2021-08-13

ACTIVE_NOT_RECRUITING

Safety of Lower Scalp Cooling Temperature to Prevent Hair Loss From Chemotherapy in Breast Cancer PatientsNCT04180579 · 2019-11-26

ACTIVE_NOT_RECRUITING

Assessing the Response Rate of Neo-adjuvant Taxotere and Trastuzumab in Nigerian Women With Breast CancerNCT03879577 · 2019-11-25

ACTIVE_NOT_RECRUITING

Axillary Reverse Mapping in Preventing Lymphedema in Patients With Breast Cancer Undergoing Axillary Lymph Node DissectionNCT03927027 · 2019-07-29

ACTIVE_NOT_RECRUITING

Adjuvant Palbociclib in Elderly Patients With Breast CancerNCT03609047 · 2019-06-14

ACTIVE_NOT_RECRUITING

Increasing Patients' Engagement in Breast Cancer Surgery Decision-MakingNCT03766009 · 2019-06-05

ACTIVE_NOT_RECRUITING

Assessing the Response Rate of Neo-adjuvant Paclitaxel (Taxol) in Nigerian Women With Breast CancerNCT03058939 · 2018-11-01

Occupational Therapist-Led Work Intervention in Facilitating Work Maintenance or Re-entry to the Workforce in Patients With Stage I to III Breast Cancer Undergoing ChemotherapyNCT03723863 · 2018-10-25

Effect of Physical Training Program on the Exercise Adherence for Breast Cancer SurvivorNCT06771635 · 2018-06-11

Vaccine to Prevent Recurrence in Patients With HER-2 Positive Breast CancerNCT03384914 · 2018-02-19

ACTIVE_NOT_RECRUITING

The Differential Impact of Proton Beam Irradiation Versus Conventional Radiation on Organs-at-risk in Stage II-III Breast Cancer PatientsNCT03270072 · 2017-10-26

ACTIVE_NOT_RECRUITING

Novel Social Media Intervention For Older Br CA PatientsNCT02639208 · 2016-02-08

Evaluating Mass Spectrometry And Intraoperative MRI In The Advanced Multimodality Image Guided Operating Suite (Amigo) In Breast-Conserving TherapyNCT02335671 · 2015-02-01

Study the Usefulness of Bio-impedance Spectroscopy in the Early Assessment of Breast Cancer Related LymphoedemaNCT01599039 · 2012-05-01

Neoadjuvant Chemotherapy With Docetaxel and Gemcitabine in Locally Advanced Breast CancerNCT01352494 · 2011-05-01

Quantitation of Endothelial Progenitor Cells as Markers of Tumor Angiogenesis in Breast CancerNCT00393341 · 2006-10-01

Stress and Immunity Breast Cancer ProjectNCT03578627 · 1994-05-01

Common interventions

Leading sponsors

Dana-Farber Cancer Institute5 Memorial Sloan Kettering Cancer Center4 Alliance for Clinical Trials in Oncology2 Case Comprehensive Cancer Center2 European Organisation for Research and Treatment of Cancer - EORTC2 George Washington University2 Massachusetts General Hospital2 University Health Network, Toronto2 University of Chicago2 Affiliated Hospital of Jiangnan University1 Barbara Ann Karmanos Cancer Institute1 Baylor Breast Care Center1 Beni-Suef University1 Branch Office of "Hadassah Medical Ltd"1 Brust-Zentrum AG1

Trial status mix

RECRUITING17

ACTIVE_NOT_RECRUITING14

COMPLETED11

NOT_YET_RECRUITING6

UNKNOWN4

WITHDRAWN2

TERMINATED1

Phase mix

NA24

PHASE216

PHASE35

PHASE12

EARLY_PHASE11

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.